RSS   Newsletter   Contact   Advertise with us

Marinus Pharmaceuticals appoints Scott Braunstein as executive chairman

Share on Twitter Share on LinkedIn
Staff Writer | Branford, Conn., USA | February 27, 2019
Scott BraunsteinMarinus Pharmaceuticals, a biopharmaceutical company, announced that Scott Braunstein, currently a director on the company’s board, has been appointed executive chairman.
Dr. Braunstein has served on the Board of Marinus since September 2018 and brings over 20 years of expertise in the pharmaceutical and biotechnology industry.

Dr. Braunstein is currently an operating partner at Aisling Capital.

Prior to that, Dr. Braunstein served as chief operating officer at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the clinical and commercial development of products for acute care practitioners and their patients.

Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management, and spent 12 years at J.P. Morgan Asset Management in various capacities with the U.S. Equity team and the Global Healthcare team.

He currently serves on the Board of Directors of Esperion, Constellation Pharmaceuticals, Ziopharm, Trevena, and Site One, and as chairman at ArTara Therapeutics.

Dr. Braunstein began his career as a practicing physician, also serving as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center.

Dr. Braunstein holds an M.D. from the Albert Einstein College of Medicine.